Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 46
- Registration Number
- NCT03003520
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇦🇹Hanusch Krankenhaus, Wien, Austria
🇩🇰Odense Universitetshospital, Odense C, Denmark
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03004105
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT03000452
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 36
- Registration Number
- NCT02997332
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 61
- Registration Number
- NCT02997995
- Locations
- 🇪🇸
HU Arnau de Vilanova, Lleida, Spain
🇫🇷Centre François Baclesse, Caen, France
🇫🇷Institut Jean Godinot, Reims, France
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT02978482
- Locations
- 🇨🇳
Research Site, Changchun, China
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 67
- Registration Number
- NCT02963831
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT02962063
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02953457
- Locations
- 🇺🇸
The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Prisma Health-Upstate
- Target Recruit Count
- 150
- Registration Number
- NCT02938793
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.